1. Volume 385, Issue 9980, Pages 1843-1852 (May 2015)
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group 
Lieke H J Simkens, MD, Harm van Tinteren, PhD, Anne May, PhD, Albert J ten Tije, MD, Geert-Jan M Creemers, MD, Olaf J L Loosveld, MD, Felix E de Jongh, MD, Frans L G Erdkamp, MD, Zoran Erjavec, MD, Adelheid M E van der Torren, MD, Jolien Tol, MD, Hans J J Braun, MD, Peter Nieboer, MD, Prof Jacobus J M van der Hoeven, MD, Janny G Haasjes, MD, Rob L H Jansen, MD, Jaap Wals, MD, Annemieke Cats, MD, Veerle A Derleyn, MD, Aafke H Honkoop, MD, Linda Mol, MSc, Prof Cornelis J A Punt, MD, Dr Miriam Koopman, MD 
The Lancet 
Volume 385, Issue 9980, Pages (May 2015)
DOI: /S (14)
Copyright © 2015 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
The Lancet  , DOI: ( /S (14) )
Copyright © 2015 Elsevier Ltd Terms and Conditions

3. Figure 2
Kaplan-Meier analysis for progression-free and overall survival
(A) PFS1. (B) PFS2. (C) Time to second progression on any treatment. (D) Overall survival. PFS2=progression-free survival after reintroduction with CAPOX-B.
The Lancet  , DOI: ( /S (14) )
Copyright © 2015 Elsevier Ltd Terms and Conditions

4. Figure 3 Subgroup analyses for PFS2 (A), and overall survival (B)
HRs for subgroups are shown with 99% CI, and HR for overall with 95% CI. The numbers in brackets are the number of patients for whom that baseline characteristic is unknown.
The Lancet  , DOI: ( /S (14) )
Copyright © 2015 Elsevier Ltd Terms and Conditions